Project Grant R01CA308066
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $560K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Project Grant Award Summary Rockefeller University received a $100,228 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded December 1, 2026, with a completion date of May 31, 2028. The grant supports research into the molecular mechanisms and pharmacological modulation of Multidrug Resistance Protein 1 (MRP1), a primary driver of chemoresistance in cancer patients. The research addresses the critical challenge that drug...
- Federal Grant Award Summary The National Cancer Institute awarded a $2.49M Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research, effective August 1, 2025, through July 31, 2030. This research initiative comprises three integrated projects investigating lipid metabolism as a determinant of ferroptosis sensitivity in cancer cells. Project 1, led by Dr. Xuejun Jiang at Memorial Sloan Kettering Cancer Institute, examines how...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York $501,422 under the Cancer Biology Research program (CFDA 93.396) on May 1, 2026, for a project titled "Advancing a Novel Synthetic Lethal Target by Exploiting Ribosomal Stress in CH9P21.3-Deleted or MSI-H Cancers." The project will run through April 30, 2031, and focuses on developing precision oncology therapies targeting the PELO-HBS1L...
- Federal Project Grant Award Summary New York University School of Medicine received a $684,529 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026 through June 30, 2031. This fundamental cancer biology research project investigates SHP2 (PTPN11) signaling mechanisms, focusing on understanding how this protein-tyrosine phosphatase functions as a positive regulator of receptor tyrosine kinase (RTK) signaling...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded a $388,546 Project Grant to the University of Texas Health Science Center at Houston effective June 1, 2026, through May 31, 2031. The research project, "Targeting the Golgi Secretory Pathway in Chromosome 3Q-Amplified Human Cancer," addresses a significant gap in targeted therapies for non-small cell lung cancers (NSCLC) lacking actionable mutations...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center a $680,129 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2031. This five-year research initiative develops drug-delivery systems and diagnostic imaging tools to enhance preoperative liver growth in cancer patients undergoing hepatic resection. The project addresses critical clinical needs by creating resorbable polymeric...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $667,041 Project Grant to the University of Pennsylvania on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to validate and credential patient-derived xenograft (PDX) models of hepatocellular carcinoma (HCC). The project, which extends through February 28, 2031, addresses a critical gap in preclinical cancer research by developing rigorous validation and credentialing criteria for patient-derived...
- Federal Project Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $687,593 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on May 12, 2026, with completion targeted for April 30, 2031. The award funds fundamental cancer biology research investigating cysteine acquisition and utilization mechanisms in lung adenocarcinoma. The research will deliver scientific insights into how tumor cells...